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Abstract
Background—Beta-blocker therapy after acute myocardial infarction (MI) improves survival. 
Beta-blocker doses used in clinical practice are often substantially lower than those used in the 
randomized trials establishing their efficacy.
Objective—This study evaluated the association of beta-blocker dose with survival after acute 
MI, hypothesizing that higher dose beta-blocker therapy will be associated with increased 
survival.
Methods—A multicenter registry enrolled 7,057 consecutive patients with acute MI. Discharge 
beta-blocker dose was indexed to the target beta-blocker doses used in randomized clinical trials, 
grouped as >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of target dose. Follow-up 
vital status was assessed, with the primary endpoint of time-to-death right-censored at 2 years. 
Multivariable and propensity score analyses were used to account for group differences.
Results—Of 6,682 with follow-up (median 2.1 years), 91.5% were discharged on beta-blocker 
(mean dose 38.1%). Lower mortality was observed with all beta-blocker doses (p < 0.0002) versus 
no beta-blocker therapy. After multivariable adjustment, hazard ratios (HRs) for 2-year mortality 
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compared with the >50% dose were 0.862 (95% confidence interval [CI]: 0.677 to 1.098), 0.799 
(95% CI: 0.635 to 1.005), and 0.963 (95% CI: 0.765 to 1.213) for the >0% to 12.5%, >12.5% to 
25%, and >25% to 50% of target dose, respectively. Multivariable analysis with an extended set of 
covariates and propensity score analysis also demonstrated that higher doses were not associated 
with better outcome.
Conclusions—These data do not demonstrate increased survival in patients treated with beta-
blocker doses approximating those used in prior randomized clinical trials compared with lower 
doses. These findings provide the rationale to re-engage in research to establish appropriate beta-
blocker dosing following MI to derive optimal benefit from this therapy.
(The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction 
[OBTAIN]: NCT00430612)
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Beta-blocker therapy following myocardial infarction (MI) improves survival. On the basis 
of randomized clinical trials (1,2) and large observational studies (3–5), guidelines for 
management of patients after ST-segment elevation MI (6) and non-ST-segment elevation 
MI (7) recommend beta-blocker therapy in essentially all post-MI patients without 
contraindications. The randomized clinical trials did not assess the effects of different doses 
of beta-blockers and there have been no large-scale studies that have addressed this. While 
the guidelines do not refer to specific beta-blockers or doses, basic evidence-based medicine 
principles support the use of beta-blockers that have been studied in trials at the doses used/
targeted; trials that report dosing indicate that the majority of patients achieved target doses. 
However, clinically used beta-blocker doses are substantially lower (8,9). The impact of this 
large scale underdosing of beta-blockers on the beneficial effects of beta-blocker therapy is 
unknown. Analyses of post-MI beta-blocker trials have related mortality reduction to heart 
rate reduction (10,11); as heart rate reduction is dose-dependent, this supports the notion that 
there could be a dose-dependent reduction in mortality. The OBTAIN (Outcomes of Beta-
Blocker Therapy After Myocardial INfarction) study is an observational multicenter registry 
in which beta-blocker dosing information was collected in all patients with acute MI at 
participating centers to assess the effect of dose on survival. The OBTAIN hypothesis was 
that higher dose beta-blocker therapy is associated with increased survival.
Methods
Study Design and Oversight
OBTAIN, initiated in 2007, was a companion registry to the PACE-MI (PACEmaker and β-
blocker therapy post-Myocardial Infarction) trial (12). Detailed information on beta-blocker 
dosing was collected in the registry. There were 26 participating centers in the United States 
and 1 in Canada. When the trial was terminated in 2009, it was noted that beta-blocker 
utilization was nearly universal, but that most patients were treated with doses ≤25% of the 
target doses used in clinical trials. At that time, the decision was made to continue the 
registry and evaluate vital status for at least 2 years to test the hypothesis that there is a dose-
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response relationship in the beneficial effect of beta-blocker therapy on survival. After 
protocol modification to include vital status assessment and resubmission for Institutional 
Review Board approval, 21 of the original sites continued to participate (including 92% of 
the registry patients). An additional 5 U.S. sites were recruited.
The study was funded by the National Heart, Lung and Blood Institute (NHLBI). An 
Observational Study Monitoring Board, appointed by the NHLBI, monitored study conduct. 
The study was approved by each site’s Institutional Review Board with a waiver of consent 
for registry enrollment. Participating centers and study committees and personnel are listed 
in Online Appendix 1.
Patients
Consecutive patients admitted with acute MI at participating sites were entered into the 
registry. Acute MI was diagnosed by: 1) either creatine kinase elevation >2 times or 
troponin elevation >3 times the upper limit of normal; and 2) either chest pain (or equivalent 
symptoms suggestive of MI) or electrocardiographic changes consistent with MI.
Basic demographic, historical, and hospitalization information, as well as information 
regarding the index MI, was collected. Discharge beta-blocker type and dose were recorded. 
All data were collected at the site and deidentified patient information was entered in a web-
based electronic data capture system.
Beta-Blocker Dosing
Beta-blocker type and dose was chosen by the managing physician. For the purposes of this 
study, target doses for the most commonly used beta-blockers were: metoprolol 200 mg/day 
(13,14); carvedilol 50 mg/day (15) (CoregCR equivalent dose 80 mg/day); propranolol 180 
mg/day (16); timolol 20 mg/day (17); bisoprolol 10 mg/day (18); and atenolol 100 mg/day 
(19). On the basis of the dose administered, a proportion of the target dose was calculated 
(administered/target dose) only for patients taking 1 of these beta-blockers. Beta-blocker 
doses were divided into 5 pre-specified groups: no beta-blocker, >0% to 12.5%, >12.5% to 
25%, >25% to 50%, and >50% of the target dose.
Study Endpoint
The pre-specified endpoint for this study was time to all-cause mortality with survival right-
censored at 2 years. Vital status was assessed by either chart review, the Social Security 
Administration Death Master File, or direct communication with the patient/family. Per 
protocol, vital status was assessed 1 and 2 years after MI. Follow-up using the Social 
Security Administration Death Master File incorporated a 6-month delay to account for the 
lag time in recording deaths. Particularly for sites that participated in the original registry, 
longer-term follow-up (3+ years) was available.
Statistical Analysis
Patient characteristics were summarized as mean ± SD or count (%). Differences among 
groups were compared using chi-square tests for categorical variables and analysis of 
variance for continuous variables. Distribution-free rank sum tests were used for variables 
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that deviated from normality. The median (interquartile range) was used to summarize these 
variables. The Kaplan-Meier method was used to calculate 1-, 2-, and 3-year survival in 
each study group.
Pre-specified analysis of the effect of the 5 pre-specified groups on 2-year survival was 
tested by comparing Kaplan-Meier survival curves with a log-rank test. Cox proportional 
hazards regression was used to test for the independent effects of beta-blocker dosing on 
survival. The following pre-specified patient characteristics were used in multivariable 
adjustment: age; sex; white race; Hispanic ethnicity; cardiac enzymes; left ventricular 
ejection fraction; diabetes; hypertension; hypercholesterolemia; ST-segment elevation MI; 
lytic therapy; primary percutaneous coronary intervention; length of stay; and other 
discharge medications (aspirin, angiotensin-converting enzyme [ACE] inhibitors/angiotensin 
receptor blockers (ARB), and statins). A pre-specified secondary analysis was performed 
comparing the outcomes for low-dose (≤25%) and high-dose (≥50%) beta-blocker therapy.
Further sensitivity analyses of the effect of the 4 beta-blocker doses on outcome included 
evaluation of 3-year outcomes. Multivariable analysis included an expanded set of all 
covariates listed in Table 1, including use of carvedilol versus metoprolol. Random effects 
(shared frailty model) were also included for each of the recruiting hospitals to better model 
differences in mortality among them. Quadratic and cubic polynomial terms for continuous 
predictors were included to account for potential non-linearity.
Propensity score analysis was also performed as an alternative adjustment for patient 
differences in the 4 beta-blocker dose groups. To calculate the propensity score, we used 
mixed effects linear regression with random effects of the recruiting centers, continuous 
discharge beta-blocker dose (% of target dose) as a dependent variable, and the expanded 
control variable set reported in Table 1 (including quadratic and cubic polynomial terms for 
continuous predictors). In that way, the propensity scores represent the predicted discharge 
beta-blocker dose, given the extended set of patient characteristics. The propensity score 
was used as control variable in the proportional hazards frailty regression model. Further 
details are provided in Online Appendix 2.
All tests were 2-tailed and conventional 5% significance level was used. A gatekeeper 
hypothesis strategy for type I error control was utilized for pre-specified study endpoints—
alpha levels were to be adjusted for subsequent tests if the gatekeeper null hypothesis were 
rejected. Analyses were performed using SAS software version 9.4.
Results
The registry included 7,057 patients. In-hospital mortality was 4.7%; 43 patients were lost to 
follow-up. Table 1 displays baseline characteristics of the 6,682 patients discharged alive, 
stratified by beta-blocker use. The mean age across groups was 63 to 65 years, with male 
predominance. Small to moderate group differences were noted for most characteristics.
Discharge therapy included beta-blockers (91.5%), aspirin (92.6%), ACE inhibitors/ARBs 
(66.3%), and statins (86.3%). There were 567 patients (8.5%) discharged without beta-
blocker therapy. Reasons provided for not administering beta-blockers included low blood 
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pressure (26%), conduction system disease (16%), pulmonary disease (17%), heart failure 
(9%), drug use (5%), debilitation (5%), and other (22%).
Beta-blockers administered at discharge included metoprolol (67.7%), carvedilol (24.3%), 
atenolol (3.8%), bisoprolol (2.8%), propranolol (0.2%), and others (1.1%). Of the patients 
discharged on a beta-blocker, 24.0%, 37.2%, 25.5%, and 13.4% received >0% to 12.5%, 
>12.5% to 25%, >25% to 50%, and >50% of the target dose, respectively. The mean 
administered dose was 38.1% of the target dose. Median follow-up was 2.1 years (IQR: 2.0 
to 2.5). At last follow-up (n = 3,581), 52.4%, 20.2%. and 20.2% were taking the same, a 
higher, or a lower dose, respectively, with a 3.8% discontinuation rate and a 3.4% initiation 
rate in patients not discharged on beta-blockers. From discharge to 1 year, of the patients 
treated with >12.5% to 25% of the target dose, only 4% were subsequently in the >50% of 
target dose group. Of the patients treated with >50% of the target dose, only 12% were 
subsequently treated with ≤25% of target dose. In this cohort, beta-blocker therapy was 
associated with an unadjusted 51% (adjusted 45%; 95% confidence interval [CI]: 33% to 
55%) lower mortality compared to no beta-blocker therapy.
At 2 years, there were a total of 831 deaths (post-discharge mortality of 12.4%). The Central 
Illustration, Panel A shows the Kaplan-Meier curves for the primary analysis. Table 2 
provides the hazard ratios relative to no beta-blocker and to the >50% target dose. 
Multivariable analysis identified that all tested parameters were independently related to 
survival (Table 3). After the pre-specified multivariable adjustment, relative to the >50% 
target dose, mortality did not differ for the >0% to 12.5% and >25% to 50% doses and was 
borderline statistically significant in those taking >12.5% to 25% of the target dose, but not 
after multivariable adjustment with the extended set of covariates (Table 2A).
The Kaplan-Meier curves for low-dose (≤25%) versus high-dose (≥50%) beta-blocker 
therapy (Central Illustration, Panel B) show a significantly higher mortality with high-dose 
therapy as compared with low-dose therapy (hazard ratio [HR]: 1.319; 95% CI: 1.133 to 
1.536; p = 0.0004). After multivariable adjustment (Table 3), there was higher mortality 
(HR: 1.167; 95% CI: 0.998 to 1.363; p = 0.05) with high- versus low-dose therapy, but not 
after multivariable adjustment with the extended set of covariates (Table 2A).
Table 2B demonstrates the multivariable hazard ratios with extended follow-up to 3 years, 
using the pre-specified multivariable analysis, and the analyses focusing on the 4 beta-
blocker dose groups using multivariable analysis with the expanded set of covariates and the 
propensity score analysis. Relative to the >50% dose group, there were no significant 
differences between the >0% to 12.5% and >25% to 50% dose groups. Although there were 
lower hazard ratios in the >12.5% to 25% dose group, these were not consistently significant 
across all analyses. As the >12.5% to 25% group was the largest group and experienced the 
lowest mortality, Figure 1 shows the hazard ratios relative to the >12.5% to 25% dose group. 
Increased hazard ratios were noted in the >0% to 12.5% (expanded multivariable HR: 1.092, 
95% CI: 0.896 to 1.331, p = 0.38; propensity score HR: 1.394, 95% CI: 1.148 to 1.692, p = 
0.0008) and >25% to 50% (expanded multivariable HR: 1.176, 95% CI: 0.973 to 1.420, p = 
0.09; propensity score HR: 1.248, 95% CI: 1.035 to 1.505, p = 0.02) dose groups.
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Subgroup analyses were performed for patients taking metoprolol versus carvedilol, ST-
segment elevation MI versus non-ST-segment elevation MI, patients with LVEF above or 
below 40%, and patients who were or were not revascularized during their admission 
(primary PCI, later PCI, or surgery). There was a significant interaction with the effect of 
beta-blocker dose only for revascularization (p = 0.037). In revascularized patients, the HRs 
compared with the >50% dose were 0.649 (95% CI 0.472 to 0.891), 0.546 (95% CI: 0.403 to 
0.740), and 0.768 (95% CI: 0.563 to 1.048) for the >0% to 12.5%, >12.5% to 25%, and 
>25% to 50% doses, respectively. In nonrevascularized patients, these effects were less 
pronounced (HR: 1.294; 95% CI: 0.940 to 1.782 vs. HR: 0.963; 95% CI: 0.709 to 1.308; vs. 
HR: 1.223; 95% CI: 0.901 to 1.660) for the >0% to 12.5%, >12.5% to 25%, and >25% to 
50% doses, respectively.
Discussion
This study was designed to evaluate whether higher-dose beta-blocker therapy is associated 
with increased survival compared to lower doses in patients discharged alive from the 
hospital after MI. Contrary to our hypothesis, improved outcome with higher dose beta-
blocker therapy, specifically the target beta-blocker doses used in prior randomized clinical 
trials, was not observed. While baseline differences in the treatment groups preclude a 
definitive determination of the dose-response relationship between beta-blocker dose and 
mortality post-MI, the lowest observed mortality was at 25% of the target dose (i.e., 
metoprolol 50 mg/day). However, there was not a consistent statistically significant 
reduction in mortality with this dose with the various analyses used to adjust for baseline 
differences among the groups. In relation to these findings, the existing evidence base from 
randomized clinical trials incorporated primarily target doses and provided no information 
regarding the dose-response of post-MI beta-blocker therapy on subsequent survival. Thus, 
the present registry data remain consistent with prior clinical trials that show a benefit of full 
dose beta-blocker therapy. Yet, they raise the question of whether lower doses may result in 
equivalent outcomes compared to the target dose. These data support the need for further 
testing to determine optimal dosing of beta-blockers after MI.
The intriguing findings from this registry require careful explication, as there are several 
potential explanations for these results. First, it remains possible, though unlikely, that target 
dose beta-blocker therapy is still associated with better survival than lower doses; this would 
be possible in this registry if some unmeasured confounder(s) were unequally represented in 
the target and lower-dose groups making the former a substantially higher risk group than 
the low-dose group in which accounting for this parameter would substantially alter 
(reverse) the estimates of the adjusted survival. It is more feasible that further adjusting for 
other unmeasured confounders would show that there is not a strong dose-dependence of 
beta-blocker effect. In other words, once one achieves a threshold dose, further increments 
in the dose do not provide further benefit. In addition, the registry data are consistent with a 
greater benefit at lower doses than the target doses used in the clinical trials, but this would 
need to be tested prospectively. Finally, it is conceivable that there is not a single optimal 
dose for all post-MI patients with some patients benefiting from lower doses and some 
patients requiring higher doses. As the trial hypothesis was that higher doses would be 
associated with improved outcomes, an a priori noninferiority analysis was not proposed to 
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show noninferiority of the >12.5% to 25% target dose. While it would not be appropriate to 
conduct noninferiority testing with a margin determined in a post-hoc manner, our post-hoc 
calculations showed that the noninferiority margin that would change the conclusion about 
noninferiority of the >12.5% to 25% target dose would have to be relatively small. Further 
studies will need to determine whether fixed target dosing for all post-MI patients or 
individualized dosing on the basis of patient or MI characteristics will optimize outcomes.
A variety of data support the biologic plausibility for the lack of a uniform improved 
survival with target dose versus low-dose beta blocker therapy post-MI. As most of the 
randomized clinical trial data for the beneficial effects of beta-blocker therapy were derived 
before thrombolysis, primary angioplasty, and routine use of aspirin, statins, and ACE-
inhibitors, the benefit of beta-blockers in the modern era has often been questioned. Meta-
analyses including >50,000 patients from the early randomized trials of post-MI beta-
blocker therapy (1,2) demonstrated 19% to 23% reductions in mortality. The more 
contemporary CAPRICORN (15) randomized trial of carvedilol in post-MI patients with left 
ventricular ejection fraction ≤40% also demonstrated a 23% reduction in all-cause mortality. 
Notably, in CAPRICORN, 74% of patients achieved the target dose and an additional 11% 
achieved 50% of the target dose. Large-scale observational studies (3–5) from Medicare 
databases documented the benefits of beta-blocker therapy in an era of rampant underuse. 
The largest contemporary trial, COMMIT (ClOpidogrel and Metoprolol in Myocardial 
Infarction Trial) (20), randomized 45,852 patients with suspected acute MI to metoprolol 
(initially intravenous followed by 200 mg orally daily) versus placebo and noted no 
reduction in mortality at 28 days. A 2014 meta-analysis (21) comparing the effect of beta-
blockers on mortality after MI in the pre- versus post-reperfusion eras noted no benefit in the 
post-reperfusion era. Finally, a contemporary observational report identifed a 15% reduction 
in mortality with beta-blocker therapy after MI (22). The changes in the therapeutic 
landscape of MI care and the variable reported outcomes provide further rationale to re-
explore the effect of beta-blocker treatment and dosing on outcomes after MI.
Several studies (8,9) have noted beta-blocker underdosing relative to clinical trial doses. 
There are scant data and no randomized clinical trial data addressing whether this represents 
an acceptable or “poor” clinical practice. A 1998 retrospective cohort study (23) of 1,165 
post-MI patients, of whom 365 were treated with beta-blockers, is the only prior study 
evaluating the effect of dose on outcome. Unadjusted mortality at a mean follow-up of 
approximately 2 years in those treated with ≥50% and <50% of the target dose was 6.9% 
and 3.4%, respectively. Multivariable analysis demonstrated a 67% reduction in 
cardiovascular mortality associated with low-dose beta-blockers. Interestingly, a study of 
208 post-MI patients (24), of whom 154 were treated with a mean beta-blocker dose of 34% 
of the target dose, demonstrated a 60% reduction in all-cause mortality at a mean follow-up 
of 58.5 months. As no prior randomized clinical trials evaluated whether low-dose or target-
dose beta-blocker therapy results in improved outcomes after MI, the OBTAIN registry 
establishes clinical equipoise for this issue and justifies further evaluation.
Dose-dependent effects of beta-blockers in the setting of heart failure have been examined 
with somewhat inconsistent results (25–27). Whereas some trials (26,27) have shown a 
direct relationship of dose to survival, a meta-analysis (28) demonstrated no significant 
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difference in mortality reduction between the trials in which patients received ≥50% of the 
target dose versus low doses (RR: 0.74 and 0.78, respectively), though a relationship to heart 
rate reduction was noted. Although there may be some commonality of purpose in the use of 
beta-blockers post-MI and in heart failure, it is also possible that the dose-response 
relationships are different, reflecting important differences in underlying global and regional 
autonomic abnormalities, particularly in the degree of sympathoexcitation, between the 2 
conditions. Furthermore, it is possible that the dose-response relationships for the beneficial 
effects of beta-blockers, even among subgroups of patients with MI, may be flatter than the 
dose-response relationships for adverse effects, including those that may affect the 
conduction system or cause metabolic side effects, such as hyperlipidemia or insulin 
resistance (29).
The predominant mechanisms of benefit for beta-blocker therapy after MI are reductions in 
ischemia, reinfarction, and sudden death. In the era of revascularization, aspirin, and statin 
use, it is plausible that the contribution of beta-blocker therapy to reductions in ischemia and 
reinfarction are not as prominent as when the initial beta-blocker clinical trials were 
performed. In fact, a 41% reduction in sudden death was reported in a pooled analyis of 5 
studies evaluating trials of metoprolol post-MI, accounting for virtually all the difference in 
total mortality between the metoprolol and placebo-treated patients (30). While it is possible 
that this benefit plays an even more prominent role in the modern era of post-MI treatment, 
it is also interesting to note that the presenting rhythms for out-of-hospital cardiac arrest 
have undergone transformation over the last decades, with a decline in ventricular 
fibrillation and an increase in pulseless electrical activity/asystole (31). The natural history 
of this change is uncertain, but may reflect, at least in part, the use of beta-blockers. Of 
particular interest is a report that noted an adjusted odds ratio of 5 for beta-blocker use 
among out-of-hospital cardiac arrest survivors presenting with pulseless electrical activity 
versus ventricular fibrillation (32). The potential importance of bradyarrhythmias was 
further highlighted in the CARISMA (Cardiac Arrhythmias and Risk Stratification After 
Acute Myocardial Infarction) study (33), in which post-MI patients with LVEF <40% 
received an implantable cardiac monitor. At 2-year follow-up, 17% of patients had either 
high-degree atrioventricular block, significant sinus bradycardia, or sinus arrest.
Personal factors that might influence the optimal beta-blocker dose include individual risk 
on the basis of patient and MI characteristics, genetic polymorphisms, and observed beta-
blocker effect. For example, the OACIS (Osaka Acute Coronary Insufficiency Study) 
registry (34) found improved survival with beta-blocker therapy after ST-segment elevation 
MI only in the higher-risk subgroup. There are data suggesting that beta-adrenergic receptor 
polymorphisms influence outcomes in acute coronary syndromes and heart failure (35–38), 
but the dose-response effect is unknown. Furthermore, genetic polymorphisms may affect 
beta-blocker metabolism and concentration (39,40). A number of analyses have suggested 
that mortality reduction post-MI is related more to the degree of heart rate reduction than to 
beta-blocker type (10,11). Whether these factors can allow for optimal titration of beta-
blocker dose for an individual post-MI patient requires further study.
There are several reasons for the current high rate of low-dose beta-blocker therapy post-MI. 
This may represent either physician or patient inertia. Some patients may not be able to 
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tolerate higher doses for hemodynamic reasons or due to noncardiac side effects or a more 
severe medical condition. Finally, advanced conduction system or myocardial disease may 
also preclude dose up-titration. There is no a priori reason for these factors to bias toward 
greater benefit with lower doses.
An important caveat for the current findings is that they do not represent randomized clinical 
trial results. As such, multiple beta-blockers were used and the doses were indexed to doses 
used in clinical trials. While this does not assure equivalent effects, it should be noted that 
93% of the treated patients in this registry received either metoprolol or carvedilol, which 
was accounted for in the sensitivity analyses. In addition, the survival analysis was indexed 
to the discharge beta-blocker dose. Although dose changes do occur over time, only a 
minority of patients had their doses up-titrated. Being a registry, there was also nonuniform 
distribution of risk factors among groups. In addition, the specific rationale for the 
individual dosing regimens is unknown. Thus, the multivariable/propensity score analyses 
may have incompletely adjusted for these differences and there may be unmeasured 
covariates, such as the extent of coronary artery disease or follow-up heart rate and blood 
pressure, which may affect the findings. Yet multivariable adjustment and propensity score 
analyses consistently showed no greater benefit with full-dose beta-blocker therapy, contrary 
to the orginal hypothesis. Thus, despite these limitations, it is apparent that there is need to 
stimulate further randomized trials of post-MI beta-blocker therapy from their currently 
dormant state.
Current practice is characterized by the use of low-dose beta-blocker therapy post-MI. To 
date, no data support this practice, as all the randomized clinical trials used higher target 
doses. As these trials did not perform dose titration studies, the present findings are not in 
conflict with the randomized clinical trial data. Importantly, further research is needed to 
establish optimal (personalized) beta-blocker dosing following MI.
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COMPETENCY IN PATIENT CARE: Therapy with beta-adrenergic antagonist drugs is 
recommended for patients after MI, but the most commonly prescribed doses are one-
quarter of the dose evaluated in the randomized clinical trials that demonstrated efficacy 
and optimum doses have not been validated.
TRANSLATIONAL OUTLOOK: Additional research is needed to compare various doses 
of beta-blockers in survivors of MI and identify factors that influence optimum dose 
selection.
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Figure 1. Adjusted Hazard Ratios for 3-Year Survival With Multivariable Analyses and 
Propensity Score Analysis Relative to the >12.5–25% of Target Dose Group
Adjusted hazard ratios for 3-year survival with multivariable analysis incorporating the pre-
specified variable set, multivariable analysis incorporating the expanded variable set, and 
propensity score analysis comparing mortality with each beta-blocker dose to the mortality 
observed in the >12.5% to 25% of the target dose group.* p < 0.03, †p < 0.001.
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Central Illustration. Beta-blockers After MI: Unadjusted Kaplan-Meier Survival Curves for the 
5 Discharge Doses Analyzed and Low and High Dose Beta-Blocker Therapy
Kaplan-Meier survival curves for (A) the primary (unadjusted) analysis comparing the 5 
discharge doses (no beta-blocker [BB] and >0% to 12.5%, >12.5% to 25%, >25% to 50%, 
and >50% of the target dose) of beta-blockers and (B) the secondary (unadjusted) analysis 
comparing low-dose (≤25% of the target dose) to high-dose (≥50% of the target dose) beta-
blocker therapy.
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Table 3
Predictors From Multivariable Analyses
A. Hazard ratios and 95% confidence intervals from multivariable analysis of 2-year mortality in the 2 pre-specified analyzed cohorts 
by predictor: 1) the 5 pre-specified dose groups (none, >0%–12.5%, >12.5%–25%, >25%-50%, >50% of the target dose) and 2) the low 
(≤25% of target dose) and high (≥50% of the target dose) dose groups.
5 Discharge Doses ≤25% vs. ≥50% of Target Dose
Predictor HR [95% CI] p Value HR [95% CI] p Value
Beta-blocker dose See Table 2 <0.001 0.857 (0.734–1.002) 0.05
Age 1.054 (1.048–1.060) <0.0001 1.057 (1.050–1.064) <0.0001
ln (Troponin) 1.070 (1.023–1.119) 0.003 1.068 (1.018–1.121) 0.008
LVEF 0.980 (0.975–0.986) <0.0001 0.981 (0.975–0.987) <0.0001
ln(LOS) (days) 1.320 (1.188–1.467) <0.0001 1.312 (1.167–1.476) <0.0001
Male Sex 1.240 (1.070–1.436) 0.004 1.213 (1.031–1.427) 0.02
White Race 0.822 (0.698–0.969) 0.02 0.824 (0.688–0.988) 0.04
Hispanic Ethnicity 0.678 (0.496–0.926) 0.02 0.665 (0.479–0.924) 0.02
Diabetes 1.453 (1.256–1.680) <0.0001 1.550 (1.320–1.820) <.0001
Hypertension 1.313 (1.090–1.581) 0.004 1.275 (1.037–1.568) 0.02
Hyperlipidemia 0.815 (0.706–0.940) 0.005 0.811 (0.693–0.949) 0.009
STEMI 0.694 (0.575–0.837) 0.0001 0.690 (0.561–0.848) 0.0004
Thrombolytic therapy 0.646 (0.445–0.937) 0.02 0.587 (0.381–0.905) 0.02
Primary PCI 0.614 (0.516–0.731) <0.0001 0.596 (0.492–0.721) <0.0001
ASA 0.599 (0.494–0.727) <0.0001 0.677 (0.539–0.849) 0.001
ACE-I/ARB 0.763 (0.662–0.878) 0.0002 0.810 (0.693–0.947) 0.008
Statin 0.752 (0.633–0.892) 0.001 0.818 (0.671–0.998) 0.05
B. Hazard ratios and 95% confidence intervals from the multivariable analysis with the extended set of covariates of 3-year mortality 
in the 4 treated beta-blocker dose groups (>0%–12.5%, >12.5%–25%, >25%–50%, >50% of the target dose).
Parameter Estimates HR (95% CI) p Value
Beta-blocker dose See Table 2
Age 1.529 (1.044–2.240) 0.03
Age (quadratic) 0.994 (0.989–1.000) 0.05
Age (cubic) 1.000 (1.000–1.000) 0.04
ln(Troponin) (cubic) 1.006 (0.999–1.013) 0.09
ln(LOS) 2.838 (0.578–13.937) 0.20
Male Sex 1.374 (1.170–1.615) 0.0001
Diabetes 1.370 (1.163–1.614) 0.0002
Hypertension 1.219 (0.999–1.487) 0.05
STEMI 0.842 (0.666–1.065) 0.15
Thrombolytic therapy 0.739 (0.498–1.098) 0.13
Primary PCI 0.580 (0.474–0.710) <0.0001
ASA 0.784 (0.625–0.984) 0.04
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B. Hazard ratios and 95% confidence intervals from the multivariable analysis with the extended set of covariates of 3-year mortality 
in the 4 treated beta-blocker dose groups (>0%–12.5%, >12.5%–25%, >25%–50%, >50% of the target dose).
Parameter Estimates HR (95% CI) p Value
ACE-I/ARB 0.878 (0.754–1.023) 0.10
Statin 0.778 (0.632–0.958) 0.02
History of MI 1.200 (1.015–1.419) 0.03
History of CABG 1.285 (1.073–1.538) 0.006
In-hospital revascularization 0.526 (0.431–0.641) <0.0001
History of COPD 1.708 (1.411–2.066) <0.0001
History of ESRD 2.366 (1.836–3.049) <0.0001
History of CHF 1.327 (1.104–1.595) 0.003
History of CVA/TIA 1.256 (1.048–1.504) 0.01
ICD 1.360 (1.006–1.840) 0.05
BMI 0.745 (0.617–0.899) 0.002
BMI (quadratic) 1.007 (1.002–1.013) 0.01
BMI (cubic) 1.000 (1.000–1.000) 0.03
Hazard ratios for continuous variables are associated with 1 unit increase in the measure.
Abbreviations as in Table 1.
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